In a murine model of weakly immunogenic breast cancer (TSA cell line), Dewan et al. showed that the best abscopal effect was obtained with a dose of 24 Gy in 3 fractions of 8 Gy (vs 1.20 Gy and 5.6 Gy) and when the anti-CTLA-4 antibody was administered over the days following irradiation, without exceeding a 4-day interval, beyond which the benefit of this combined treatment was no longer observed [26]. This evidence concerns the gene CTLA4 and breast carcinoma.